JAK2 and myeloproliferative neoplasm: Mutant JAK2 is commonly detectable in 0.1–3% of the healthy population as clonal hematopoiesis (CH)2–7, with the vast majority of carriers not meeting or going on to develop disease-defining characteristics of MPN.